Argobio is a start-up studio dedicated to novel therapeutics aiming to nurture and launch breakthrough Biotech companies. Argobio sources innovative early-stage projects from renowned European academic research institutions with the objective of incubating these projects before company creation. The focus is on rare diseases, neurological disorders, oncology, and immunology. The studio also look to develop promising platform technologies for therapeutic products. Argobio was initiated by Kurma Partners, Bpifrance, Angelini Pharma, Evotec and Institut Pasteur who have committed 50M € to Argobio.